Catalyst Wire Dossier Catalyst Wire Dossier

IgPro20 (Hizentra)

immune globulin, human, subcutaneous · CSL Behring
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IgPro20 (Hizentra), covering 2014-12-02 to 2018-02-26. Get the full timeline:

Most recent: Clinical Trial Update: Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules [Phase 4]

See pricing